GMP Companies, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Series of private placements totaling $28.2 mil. will facilitate commercialization and development of the firm's products, including the ThromboFlex blood coagulation monitor and an anti-embolism stocking to prevent deep-vein blood clots in hospitalized patients. The financing includes a $9.5 mil. investment by Medtronic. Quest Diagnostics contributed $7.1 mil. Other investors were Motorola, Texas Pacific Group, and J&W Seligman & Co. The Fort Lauderdale-based firm has raised a total of $134 mil. since its founding in May 1999
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.